Understanding diabetes, thyroid disease, autoimmune disorders, epilepsy, cardiovascular conditions, kidney disease, asthma, and other chronic illnesses—and why personalized disease management matters before conception.
What happens when someone wants to become pregnant while living with a chronic medical condition?
Does diabetes influence early embryonic development?
Can thyroid disease affect fertility or pregnancy outcomes?
How should someone with epilepsy balance seizure control against the reproductive risks of medication?
What considerations are important for women with autoimmune disorders, hypertension, or cardiovascular disease?
And when is the best time to address these concerns?
For individuals living with chronic illness, preparing for pregnancy may require more than a standard wellness assessment.
Pregnancy creates substantial physiological demands involving cardiovascular function, endocrine regulation, metabolism, renal physiology, immune signaling, and other biological systems.
Preexisting medical conditions may influence how the body adapts to these demands.
Conversely, pregnancy may change the course of an existing illness or alter the effectiveness and safety of its treatment.
In 2008, Dunlop and colleagues published The Clinical Content of Preconception Care: Women With Chronic Medical Conditions in the American Journal of Obstetrics & Gynecology.
The authors examined how several chronic diseases influence reproductive health and how appropriate management before conception might reduce preventable complications.
Their review addressed diabetes mellitus, thyroid disease, phenylketonuria, seizure disorders, hypertension, rheumatoid arthritis, systemic lupus erythematosus, chronic kidney disease, cardiovascular disease, thrombophilia, and asthma.
They emphasized that preconception care should be integrated into routine healthcare rather than reserved exclusively for individuals actively attempting pregnancy.
Nearly two decades later, research published in The New England Journal of Medicine, along with updated recommendations from major professional organizations, has significantly refined how these conditions are managed.
For example, contemporary diabetes recommendations emphasize achieving safe glycemic targets before conception.
Randomized trials have changed the treatment of chronic hypertension during pregnancy.
Advances in neurology have improved understanding of antiseizure medication risks.
And updated rheumatology guidelines increasingly emphasize maintaining effective disease control with pregnancy-compatible medications rather than unnecessarily withdrawing treatment.
Collectively, these findings support an important principle:
The presence of a chronic medical condition does not automatically prevent a healthy pregnancy. However, informed planning, appropriate treatment, and individualized risk assessment can make a meaningful difference.
1. Why Chronic Disease Management Matters Before Pregnancy
Pregnancy should not be viewed as an isolated biological event.
It represents a major physiological transition in which multiple organ systems adapt to support maternal and fetal needs.
Cardiac output increases.
Blood volume expands.
Renal filtration changes.
Insulin resistance normally increases during pregnancy.
Thyroid hormone requirements may change.
Immune regulation adapts to support pregnancy while maintaining protection against infection.
These adaptations can interact with preexisting disease.
For someone with impaired kidney function, increased physiological demands may complicate renal management.
A person with diabetes may need adjustments in glucose monitoring and treatment.
Someone with a serious cardiac condition may have limited capacity to accommodate increased circulatory workload.
The clinical importance depends on disease severity, current stability, treatment, and individual physiology.
Consequently, a diagnosis alone is insufficient for determining pregnancy risk.
A person with well-controlled hypertension may have a substantially different risk profile from someone with severe hypertension and established organ damage.
Preconception care should distinguish these circumstances rather than classify all patients with a given diagnosis identically.
2. The Difference Between Disease Control and Disease Elimination
An important misconception is that individuals must become completely free of medical conditions before pursuing pregnancy.
For many chronic diseases, a cure is not available.
However, appropriate treatment can substantially reduce disease activity, improve physiological function, and prevent complications.
For example, thyroid hormone replacement can correct overt hypothyroidism.
Antiseizure medication can maintain seizure control.
Immunomodulatory treatment can reduce autoimmune disease activity.
Antihypertensive therapy can control blood pressure.
The goal of preconception care is therefore not necessarily to eliminate illness.
It is to establish the most appropriate clinical conditions for pregnancy.
This may involve achieving disease remission, improving metabolic control, adjusting medications, or identifying complications requiring specialist management.
It may also involve discussing whether conception should be delayed while a particular condition is stabilized.
However, decisions about pregnancy timing must respect the individual's goals and reproductive autonomy.
3. Diabetes Mellitus: Why Glycemic Control Before Conception Is So Important
Diabetes is one of the clearest examples of a chronic medical condition for which preconception management can reduce reproductive risks.
Both type 1 and type 2 diabetes may influence pregnancy.
High maternal glucose concentrations during early embryonic development are associated with increased risks of congenital abnormalities.
These include abnormalities affecting the cardiovascular and central nervous systems.
Diabetes may also increase the likelihood of miscarriage, preeclampsia, fetal overgrowth, and other complications.
The original AJOG article emphasized that the risk of congenital abnormalities increases with poorer glucose control during early pregnancy.
Because major organ development begins before many individuals recognize pregnancy, improved glucose regulation should ideally be established beforehand.
This remains a central recommendation in contemporary care.
4. What Do the 2026 ADA Standards Recommend?
The American Diabetes Association's Standards of Care in Diabetes—2026 provide specific recommendations for individuals with diabetes who may become pregnant.
For most individuals with preexisting diabetes, preconception counseling should emphasize achieving blood glucose concentrations as close to normal as safely possible.
The recommended HbA1c target before conception is ideally below 6.5%, provided this can be achieved without excessive hypoglycemia.
However, this target requires clinical judgment.
Aggressive glucose lowering that produces severe hypoglycemia is not an appropriate strategy.
The ADA also emphasizes multidisciplinary preconception care involving diabetes specialists, maternal-fetal medicine professionals, nutrition specialists, and diabetes educators when available.
Importantly, the recommendations extend beyond glucose measurements.
Assessment should include relevant diabetes complications, medication safety, cardiovascular risk, nutritional needs, and self-management capabilities.
The objective is safe metabolic control—not simply achieving the lowest possible HbA1c.
5. Continuous Glucose Monitoring and Precision Diabetes Management
Advances in glucose monitoring have expanded options for individuals with diabetes.
Continuous glucose monitoring, or CGM, measures interstitial glucose over time and provides information about glucose patterns.
Unlike a single fasting glucose measurement, CGM can reveal fluctuations throughout the day.
It can help identify postprandial hyperglycemia, nocturnal hypoglycemia, and other clinically relevant patterns.
The ADA recommends CGM for pregnant individuals with type 1 diabetes.
It may also benefit selected individuals with other forms of diabetes.
However, CGM does not replace appropriate medical management.
Data interpretation requires consideration of treatment, food intake, activity, symptoms, and pregnancy-specific targets.
Moreover, a person without diabetes does not automatically benefit from continuous glucose monitoring solely because they are preparing for pregnancy.
The strongest evidence supports its use in clearly defined clinical contexts.
6. Previous Gestational Diabetes: Why Follow-Up Matters Between Pregnancies
Gestational diabetes is diagnosed during pregnancy and may resolve after delivery.
However, its resolution does not necessarily eliminate future metabolic risk.
A history of gestational diabetes is associated with increased likelihood of developing type 2 diabetes.
It also increases the risk of gestational diabetes in a subsequent pregnancy.
The original AJOG article recognized the importance of follow-up between pregnancies.
The 2026 ADA guidelines continue to recommend screening individuals with a history of gestational diabetes before another pregnancy.
When clinically indicated, preparation may involve glucose testing, nutritional assessment, physical activity, and treatment of identified metabolic disease.
Importantly, a previous diagnosis of gestational diabetes should not be interpreted as proof that the individual has ongoing diabetes.
Appropriate testing is needed.
The goal is to identify those who would benefit from treatment before conception.
7. Thyroid Disease: An Essential Component of Reproductive Endocrinology
Thyroid hormones influence energy metabolism, cardiovascular function, thermoregulation, and numerous developmental processes.
During pregnancy, maternal thyroid hormone availability is particularly important for early fetal development.
Both hypothyroidism and hyperthyroidism may influence reproductive health.
Overt hypothyroidism can interfere with menstrual function and ovulation and is associated with adverse pregnancy outcomes when inadequately treated.
Uncontrolled hyperthyroidism may increase maternal and fetal risks, including hypertensive complications and fetal growth problems.
However, thyroid disease encompasses several distinct conditions.
Hashimoto thyroiditis, Graves disease, overt hypothyroidism, and subclinical thyroid dysfunction do not require identical management.
Accurate diagnosis is therefore essential.
8. What Changed in the 2026 American Thyroid Association Guidelines?
In 2026, the American Thyroid Association published updated guidance covering thyroid disease during preconception, pregnancy, and postpartum.
For individuals receiving levothyroxine for hypothyroidism, the guidelines support achieving biochemical euthyroidism before pregnancy.
A preconception TSH target within the normal reference interval but below approximately 2.5 mU/L may be used in appropriate patients.
However, treatment decisions depend on the actual diagnosis.
Overt hypothyroidism warrants treatment.
The evidence for treating mild subclinical hypothyroidism is more nuanced and varies according to TSH concentration, pregnancy timing, and other clinical factors.
For individuals already taking levothyroxine, pregnancy often increases thyroid hormone requirements.
The guidelines also emphasize the limitations of relying exclusively on TSH without considering clinical circumstances and appropriate free thyroid hormone assessment.
These recommendations reinforce the importance of established endocrine evaluation rather than treating every variation in thyroid laboratory results as a reproductive disorder.
9. Hyperthyroidism and Graves Disease
Graves disease is an autoimmune condition that can cause excessive thyroid hormone production.
During pregnancy, uncontrolled hyperthyroidism may increase the risk of complications.
However, treatment presents additional considerations because antithyroid medications can have pregnancy-related risks.
Preconception planning may involve assessing disease activity, reviewing medication options, and determining whether the patient is clinically stable.
Some individuals may be treated with antithyroid medications.
Others may have undergone definitive treatment through surgery or radioactive iodine.
For individuals previously treated with radioactive iodine, appropriate conception timing and thyroid hormone stabilization are important.
Thyroid-stimulating antibodies may remain relevant even after thyroid ablation.
The appropriate plan should be developed with an endocrinologist and obstetric specialist.
10. Phenylketonuria: A Powerful Example of Metabolic Prevention
Phenylketonuria, or PKU, is an inherited metabolic condition involving reduced activity of phenylalanine hydroxylase.
This enzyme participates in the conversion of phenylalanine to tyrosine.
When phenylalanine metabolism is impaired, blood phenylalanine concentrations can rise.
During pregnancy, excessive maternal phenylalanine exposure can interfere with fetal development.
Potential consequences include congenital heart abnormalities, microcephaly, growth restriction, and neurodevelopmental impairment.
An important distinction is that these effects can occur even when the fetus does not inherit PKU.
The maternal metabolic environment itself is relevant.
This illustrates how a specific metabolic disorder can influence development independently of direct transmission of the condition.
11. What Does Modern Guidance Recommend for Maternal PKU?
The original AJOG paper emphasized establishing metabolic control before conception.
Current recommendations continue to support this approach.
ACOG recommends that individuals with phenylalanine hydroxylase deficiency achieve phenylalanine concentrations below 6 mg/dL for at least three months before pregnancy.
During pregnancy, the recommended range is generally 2–6 mg/dL.
Management requires a carefully supervised nutritional and metabolic treatment plan.
This may involve a low-phenylalanine diet, specialized medical nutrition products, and frequent biochemical monitoring.
However, patients should not attempt to manage maternal PKU through ordinary dietary restriction alone.
Treatment requires specialist oversight because inadequate protein or energy intake can create additional risks.
Maternal PKU provides one of the clearest examples of why targeted nutritional therapy can be essential when a validated metabolic disorder is present.
12. Epilepsy: Balancing Seizure Control With Medication Safety
Epilepsy is another important condition addressed in the original AJOG article.
Uncontrolled seizures can create serious risks during pregnancy.
Certain antiseizure medications, however, may increase the risk of fetal malformations or adverse neurodevelopmental outcomes.
Consequently, medication selection requires balancing maternal seizure control with reproductive safety.
In 2024, the American Academy of Neurology, American Epilepsy Society, and Society for Maternal-Fetal Medicine published updated guidance.
The guideline emphasizes selecting treatment regimens that optimize seizure control and fetal outcomes whenever possible.
Certain medications, including lamotrigine, levetiracetam, and oxcarbazepine, may be considered when appropriate.
Valproate should generally be avoided when clinically feasible because of its established developmental risks.
However, medication suitability depends on seizure type, previous treatment response, and individual clinical circumstances.
13. Why Antiseizure Medication Should Not Be Stopped Abruptly
One of the most important patient-safety messages is that a potentially teratogenic medication should not automatically be discontinued without supervision.
For individuals with epilepsy, uncontrolled convulsive seizures can create serious medical risks.
The 2024 neurological guidelines emphasize minimizing generalized tonic-clonic and focal-to-bilateral tonic-clonic seizures during pregnancy.
They also recommend caution when attempting to withdraw or replace an effective medication after pregnancy has already begun.
Ideally, treatment decisions should be addressed before conception.
This allows time to evaluate alternatives, establish seizure control, and monitor treatment response.
Appropriate folic acid supplementation is also recommended.
However, folic acid does not eliminate every medication-associated developmental risk.
The goal is an individualized neurological treatment plan.
14. Hypertension: A Major Update Since 2008
Chronic hypertension is associated with increased risk of maternal and obstetric complications.
These may include preeclampsia, placental abruption, preterm birth, and fetal growth restriction.
The original AJOG paper recognized these risks but noted uncertainty about whether treating mild chronic hypertension improved pregnancy outcomes.
At the time, some guidelines favored delaying medication treatment until blood pressure became substantially elevated.
That approach has changed.
In 2022, researchers published the CHAP trial, Treatment for Mild Chronic Hypertension During Pregnancy, in The New England Journal of Medicine.
The randomized trial evaluated whether active treatment targeting blood pressure below 140/90 mm Hg improved pregnancy outcomes.
15. What Did the CHAP Trial Demonstrate?
The CHAP trial included 2,408 pregnant women with mild chronic hypertension.
Participants were assigned to either active treatment using pregnancy-compatible antihypertensive medications or a control strategy in which treatment was generally reserved for more severe hypertension.
The primary outcome combined several serious complications, including severe preeclampsia, medically indicated preterm birth before 35 weeks, placental abruption, and fetal or neonatal death.
The primary outcome occurred in 30.2% of the active-treatment group compared with 37.0% of the control group.
The adjusted risk ratio was 0.82.
Importantly, treatment did not significantly increase the proportion of infants who were small for gestational age.
This trial provided strong evidence supporting treatment of mild chronic hypertension during pregnancy.
It is a clear example of how randomized research can change recommendations that were uncertain in 2008.
16. Preconception Cardiovascular Assessment for Hypertension
For individuals with chronic hypertension, preparation should begin with understanding the current condition.
Relevant considerations include average blood pressure, medication use, duration of hypertension, and possible organ-related complications.
Some individuals may require evaluation of kidney function or other cardiovascular risk factors.
Medication review is especially important.
ACE inhibitors and angiotensin receptor blockers are generally avoided during pregnancy because of fetal risks.
Alternative treatment options may be appropriate.
However, medications should not be stopped abruptly without a replacement strategy.
The objective is to establish effective blood-pressure management before conception and arrange suitable monitoring during pregnancy.
17. Rheumatoid Arthritis: Why Disease Activity Matters
Rheumatoid arthritis is a chronic inflammatory autoimmune condition that primarily affects joints but may involve broader physiological systems.
Some individuals experience improvement in disease activity during pregnancy.
Others remain symptomatic.
Postpartum flares are also possible.
However, the course varies considerably.
The original AJOG paper emphasized medication safety and the importance of controlling disease before conception.
Modern management increasingly focuses on maintaining remission or low disease activity using appropriate therapies.
This is important because uncontrolled inflammatory disease can affect physical functioning, sleep, nutritional status, and overall health.
The goal is not necessarily medication withdrawal.
It is effective disease management with treatment appropriate for pregnancy.
18. Updated Rheumatology Guidance: Treating the Disease May Be Safer Than Stopping Treatment
The 2025 European Alliance of Associations for Rheumatology recommendations address antirheumatic medication use during reproduction, pregnancy, and lactation.
They emphasize early reproductive counseling for women and men receiving treatment for rheumatic disease.
They also recommend aiming for remission or low disease activity before and during pregnancy.
Importantly, the recommendations recognize that risks from untreated maternal disease must be weighed against medication-related risks.
Some antirheumatic medications have established reproductive safety data.
Others, including methotrexate and leflunomide, require pregnancy-specific precautions.
The original 2008 article classified several medications as uncertain because limited information was available at that time.
Subsequent research has improved understanding of multiple conventional and biologic therapies.
Treatment decisions should therefore be based on current medication-specific evidence rather than older broad classifications.
19. Systemic Lupus Erythematosus: A Complex Immune-Mediated Condition
Systemic lupus erythematosus, or SLE, is a multisystem autoimmune disease.
It can involve the joints, skin, kidneys, blood vessels, and other organs.
Pregnancy outcomes depend partly on disease activity and the extent of organ involvement.
For example, active lupus nephritis can substantially increase maternal and obstetric risks.
Certain autoantibodies may also influence pregnancy management.
The original AJOG paper emphasized that pregnancy outcomes are generally more favorable when lupus is clinically stable before conception.
This remains relevant.
Preconception planning should involve assessment of disease activity, organ function, medication compatibility, and other risk factors.
However, not every person with lupus has the same reproductive prognosis.
20. Hydroxychloroquine and Lupus: Why Medication Continuity Matters
Hydroxychloroquine is commonly used in the management of SLE.
It has an established role in reducing disease activity and preventing flares.
Contemporary rheumatology recommendations generally support continuation during pregnancy when clinically indicated.
This is important because unnecessary withdrawal may contribute to worsening lupus activity.
Other medications may need to be adjusted according to the patient's condition.
For example, certain immunosuppressive agents are inappropriate during pregnancy, while alternatives may be suitable.
Patients with lupus should also receive evaluation for relevant antiphospholipid antibodies and anti-Ro/SSA or anti-La/SSB antibodies when clinically indicated.
However, these tests are used in defined clinical contexts.
They should not be confused with broad, unvalidated immune panels marketed for reproductive optimization.
21. Chronic Kidney Disease: Why Renal Reserve Matters
Chronic kidney disease can influence pregnancy through several pathways.
Kidney function contributes to fluid balance, electrolyte regulation, blood pressure control, and the elimination of metabolic waste products.
Pregnancy normally increases renal blood flow and glomerular filtration.
For someone with impaired kidney function, these physiological adaptations may create additional demands.
Pregnancy risks depend on several factors, including baseline kidney function, hypertension, proteinuria, and the underlying renal diagnosis.
Some women with mild, stable kidney disease experience favorable pregnancies.
Others with advanced disease may face substantial risks.
Consequently, a diagnosis of chronic kidney disease is not sufficient to determine pregnancy prognosis.
22. What Should Be Evaluated Before Pregnancy in Kidney Disease?
Preconception assessment may include renal function, urinary protein or albumin excretion, blood pressure, medication use, and underlying disease activity.
Specialist review is particularly important for individuals with moderate or severe impairment.
Some medications used to protect kidney function outside pregnancy are not appropriate during gestation.
For example, ACE inhibitors and angiotensin receptor blockers may require treatment planning before conception.
However, these medications can provide important benefits outside pregnancy.
The goal is not simply discontinuation.
It is selecting an appropriate alternative strategy while preserving blood-pressure and kidney-disease management.
For selected patients, collaboration between nephrology and maternal-fetal medicine is essential.
23. Cardiovascular Disease: Why Pregnancy Requires Additional Hemodynamic Capacity
Pregnancy increases circulating blood volume and cardiac output.
These changes can create challenges for individuals with certain cardiovascular disorders.
Examples include significant valvular disease, cardiomyopathy, congenital heart disease, pulmonary hypertension, and some arrhythmias.
However, the risk varies widely according to the condition.
An individual with a repaired congenital heart defect and normal cardiac function may have a very different risk profile from someone with severe pulmonary arterial hypertension.
Consequently, preconception cardiovascular assessment should be condition-specific.
The original AJOG article emphasized identifying cardiovascular disease before pregnancy and reviewing potential risks.
Contemporary guidelines have significantly expanded this approach.
24. The 2025 European Society of Cardiology Pregnancy Guidelines
In August 2025, the European Society of Cardiology released updated guidelines on cardiovascular disease and pregnancy.
The guidelines emphasize multidisciplinary care before, during, and after pregnancy.
They introduce updated risk assessment approaches and further define the role of the Pregnancy Heart Team.
This team may include cardiologists, obstetric specialists, anesthesiologists, and other professionals.
Risk assessment considers the specific cardiovascular condition, severity, ventricular function, symptoms, and other relevant factors.
Some conditions may require intervention before conception.
Others may be managed with surveillance and appropriate treatment.
The objective is to provide individualized information about maternal and fetal risks while preserving informed reproductive decision-making.
25. Thrombophilia: Understanding Clotting Risk Without Overdiagnosis
Thrombophilias are conditions associated with increased tendency toward abnormal blood clotting.
They may be inherited or acquired.
Examples include factor V Leiden, prothrombin gene mutations, antithrombin deficiency, and antiphospholipid syndrome.
However, these conditions differ substantially in their clinical implications.
The original AJOG article discussed broad thrombophilia testing in relation to pregnancy complications.
Modern evidence supports a more selective approach.
Not every inherited thrombophilia requires anticoagulation during pregnancy.
Likewise, the presence of common MTHFR variants is not considered a valid reason to diagnose inherited thrombophilia or prescribe anticoagulant treatment.
Testing and treatment should be guided by a relevant personal or family history, established diagnoses, and professional recommendations.
26. What Do Hematology Guidelines Recommend?
The American Society of Hematology published evidence-based guidance on venous thromboembolism during pregnancy.
The recommendations distinguish patients according to personal history of thrombosis, specific inherited abnormalities, and other relevant factors.
For example, routine antepartum anticoagulant prophylaxis is not recommended solely because a patient is heterozygous for factor V Leiden without additional clinical indications.
Other inherited conditions and combinations of risk factors may warrant a different strategy.
Antiphospholipid syndrome also requires separate consideration.
The presence of antiphospholipid antibodies alone is not identical to a confirmed diagnosis of APS.
Appropriate clinical and laboratory criteria must be considered.
A personalized approach to clotting risk should therefore be based on validated diagnoses rather than extensive screening panels.
27. Asthma: Why Maintaining Respiratory Control Matters
Asthma is a chronic inflammatory airway condition characterized by variable respiratory symptoms and airflow limitation.
Symptoms may include wheezing, coughing, chest tightness, and shortness of breath.
Some patients experience increased asthma symptoms during pregnancy.
Others remain stable or improve.
However, poorly controlled asthma can create important maternal and fetal risks.
Severe exacerbations may impair oxygenation and require emergency treatment.
The original AJOG paper emphasized that controlling asthma is generally safer than allowing significant respiratory symptoms to persist because of concerns about medication use.
This principle remains highly relevant.
28. Updated Asthma Guidance: Do Not Stop Effective Controller Treatment
The Global Initiative for Asthma emphasizes the importance of maintaining asthma control during pregnancy.
Its guidance advises that inhaled corticosteroids should not be stopped in preparation for pregnancy or during gestation.
This recommendation reflects the benefits of avoiding asthma exacerbations and the reassuring safety evidence for commonly used inhaled therapies.
However, treatment remains individualized.
Some patients may require adjustments according to symptom control, exacerbation history, and other factors.
Preconception planning may involve reviewing inhaler technique, medication adherence, and relevant environmental triggers.
Smoking cessation and management of associated respiratory conditions can also be important.
The objective is effective asthma control—not minimizing medication exposure at the expense of respiratory health.
29. Chronic Disease, Nutrition, and Metabolic Health
Although the conditions discussed in this article are distinct, nutrition and metabolic health may be relevant across several of them.
For example, dietary patterns influence glucose management in diabetes.
Sodium intake may be relevant to some individuals with hypertension.
Patients with kidney disease may require individualized nutritional recommendations according to renal function and electrolyte balance.
Individuals with rheumatoid arthritis or lupus may experience functional limitations that affect meal preparation or physical activity.
However, these relationships do not support one universal therapeutic diet for chronic disease.
A dietary intervention appropriate for diabetes may need modification in someone with advanced kidney disease.
Likewise, some restrictive diets can create nutritional inadequacy.
Preconception nutrition should therefore be coordinated with relevant medical care and tailored to the patient's actual condition.
30. Exercise and Functional Capacity in Chronic Illness
Physical activity can support cardiovascular fitness, metabolic function, musculoskeletal health, and psychological well-being.
However, exercise prescription for individuals with chronic illness requires consideration of disease severity and functional capacity.
For someone with type 2 diabetes, appropriate exercise may improve insulin sensitivity and cardiometabolic health.
For a patient with rheumatoid arthritis, adapted resistance training may support strength and physical function.
An individual with asthma may benefit from physical conditioning when respiratory symptoms are adequately controlled.
However, some cardiovascular conditions require specific exercise restrictions or specialist assessment.
Similarly, certain autoimmune or neurological conditions may produce fluctuating functional limitations.
The goal is to establish an appropriate level of physical activity rather than apply a standardized exercise program to every patient.
31. Why Chronic Disease Is an Important Part of Reproductive Planning
The original AJOG article emphasized that contraception and family planning are important aspects of chronic disease care.
This is not because people with chronic illnesses should be discouraged from pregnancy.
It is because pregnancy timing may interact with disease stability or treatment safety.
For example, some medications require discontinuation or substitution before conception.
Certain conditions may benefit from a period of disease control before pregnancy.
Others require evaluation of organ function or treatment-related risks.
An individual may therefore choose to delay conception temporarily while preparing.
Another may decide that the benefits of proceeding outweigh particular risks.
Effective reproductive planning supports informed decisions rather than imposing one preferred outcome.
32. A Comprehensive Preconception Assessment for Chronic Medical Conditions
A useful evaluation may consider several domains.
Medical diagnoses: What conditions are present, and how have they been established?
Disease activity: Is the condition stable, improving, worsening, or fluctuating?
Organ function: Are there relevant cardiovascular, renal, endocrine, neurological, or other complications?
Medications: Are current treatments effective and compatible with pregnancy planning?
Previous pregnancies: Have there been complications related to the chronic disease?
Relevant laboratory testing: Which measurements are needed to assess disease control or treatment safety?
Functional capacity: How does the condition influence mobility, exercise tolerance, fatigue, or daily activities?
Nutritional status: Are there dietary needs or restrictions associated with the condition?
Psychological well-being: Is the individual receiving appropriate support for the emotional demands of chronic illness?
Specialist coordination: Which medical professionals should be involved before conception?
Reproductive goals: What are the patient's preferences concerning pregnancy timing and future parenthood?
The objective is to develop a coordinated assessment rather than order every available diagnostic test.
33. Practical Steps Before Pregnancy
Prospective parents living with chronic medical conditions can benefit from a structured preparation process.
Review current diagnoses. Confirm that relevant conditions have been appropriately evaluated and treated.
Assess disease control. Identify clinically meaningful measures of stability or remission.
Review all medications. Discuss reproductive safety and treatment alternatives with the appropriate prescribing clinicians.
Evaluate relevant organ function. Obtain indicated cardiovascular, renal, endocrine, or other assessments.
Address metabolic health. Manage diabetes, hypertension, and other relevant cardiometabolic conditions.
Review nutritional needs. Ensure dietary recommendations are appropriate for the individual's medical circumstances.
Establish an appropriate activity plan. Support physical function without exceeding medical limitations.
Discuss reproductive timing. Consider whether additional preparation is needed before conception.
Coordinate specialist care. Involve maternal-fetal medicine and relevant specialties when indicated.
Develop a pregnancy and postpartum plan. Anticipate necessary monitoring, treatment adjustments, and follow-up.
These steps support informed preparation without suggesting that every complication can be prevented.
34. How This Research Informs Our Preconception Care
We recognize that preconception wellness must account for the individual's broader medical history.
Chronic conditions involving metabolic, endocrine, neurological, cardiovascular, renal, immune, and respiratory systems may influence reproductive planning.
Within our conscious conception, women's wellness, functional medicine, and lifestyle coaching services, we emphasize understanding how these conditions interact with nutrition, movement, sleep, stress, and everyday functioning.
For example, a patient with diabetes may benefit from coordinated nutrition education and physical activity programming alongside prescribed medical treatment.
Someone with rheumatoid arthritis may require adapted exercise recommendations that account for pain, joint function, and disease activity.
A patient with epilepsy may benefit from education concerning sleep consistency and other relevant lifestyle considerations while continuing appropriate neurological care.
However, these interventions do not replace medical disease management.
Treatment of diabetes, thyroid disease, epilepsy, autoimmune disorders, cardiovascular conditions, or other chronic illnesses must remain coordinated with appropriately qualified medical professionals.
We also distinguish between validated clinical measurements and exploratory biological markers.
A patient with lupus may require established rheumatological testing.
That does not mean every individual benefits from an extensive cytokine panel.
Someone with thyroid disease may require appropriate thyroid function monitoring.
That does not establish the usefulness of testing every hormone metabolite.
Similarly, broad inflammatory or metabolic panels should not substitute for condition-specific evaluation.
Our objective is to support patients through education, appropriate wellness interventions, and collaborative care.
Comprehensive preconception health is not about replacing established treatment with lifestyle strategies. It is about combining effective medical management with practical, personalized support for the whole person.
Conclusion: Chronic Illness Changes the Preparation, Not Necessarily the Possibility
For individuals living with chronic medical conditions, preparing for pregnancy may involve additional considerations.
Some diseases alter reproductive physiology.
Others influence how the body responds to pregnancy.
Certain medications require adjustment before conception.
And some conditions warrant specialized surveillance or multidisciplinary care.
However, a chronic diagnosis does not automatically determine whether someone can experience a healthy pregnancy.
The original 2008 AJOG article recognized that preconception care provides an opportunity to identify meaningful risks before pregnancy begins.
Contemporary research has strengthened that perspective.
Diabetes guidelines now provide clearer targets for preconception glucose management.
Randomized trials have improved the treatment of hypertension during pregnancy.
Neurological research has clarified medication-related risks.
Rheumatology guidance increasingly emphasizes maintaining disease stability.
And cardiovascular recommendations provide more individualized approaches to evaluating pregnancy-related risk.
These advances demonstrate an important principle of evidence-based healthcare.
The objective is not to eliminate all medical uncertainty or promise a risk-free pregnancy. It is to identify clinically meaningful factors, manage conditions appropriately, and help prospective parents make informed decisions.
For some individuals, this may mean improving metabolic control.
For others, it may involve changing medications, stabilizing autoimmune disease, or obtaining specialist evaluation.
And for many, it will involve developing sustainable health behaviors that complement necessary medical care.
We believe the most effective preconception strategy begins by understanding the individual rather than treating reproductive health as an isolated system.
Because preparing for pregnancy is also an opportunity to strengthen the health, functional capacity, and long-term well-being of the person who hopes to become a parent.
Research References
Dunlop AL, Jack BW, Bottalico JN, et al. The clinical content of preconception care: women with chronic medical conditions. American Journal of Obstetrics and Gynecology. 2008;199(6 Suppl 2). https://doi.org/10.1016/j.ajog.2008.08.031
American Diabetes Association Professional Practice Committee. Management of diabetes in pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1)–S338. https://doi.org/10.2337/dc26-S015
American Thyroid Association. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. 2026. https://doi.org/10.1177/10507256261445624
American College of Obstetricians and Gynecologists. Management of women with phenylalanine hydroxylase deficiency (phenylketonuria). Committee Opinion. 2020. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/04/management-of-women-with-phenylalanine-hydroxylase-deficiency-phenylketonuria
American Academy of Neurology, American Epilepsy Society, and Society for Maternal-Fetal Medicine. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: practice guideline. Neurology. 2024. https://pubmed.ncbi.nlm.nih.gov/38748979/
Tita ATN, Szychowski JM, Boggess K, et al. Treatment for mild chronic hypertension during pregnancy. New England Journal of Medicine. 2022;386:1781–1792. https://doi.org/10.1056/NEJMoa2201295
European Alliance of Associations for Rheumatology. EULAR recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation. 2025. https://www.guidelinecentral.com/guideline/4566460/
European Society of Cardiology. 2025 ESC Guidelines for the Management of Cardiovascular Disease and Pregnancy. https://www.escardio.org/guidelines/clinical-practice-guidelines/
American Society of Hematology. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances. 2018;2:3317–3359. https://pmc.ncbi.nlm.nih.gov/articles/PMC6258928/
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2025 update. https://ginasthma.org/reports/
National Library of Medicine. Phenylalanine Hydroxylase Deficiency. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1504/
American College of Obstetricians and Gynecologists. Prepregnancy Counseling. Committee Opinion No. 762. 2019. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/01/prepregnancy-counseling